Breast cancer: deodorants in charge
Several studies noted a high incidence of breast cancer are close to the application of the anti-perspiring deodorants (the supéro-external quadrant) and an increasingly frequent use of these products.
On the basis of these reports, several scientific teams sought to establish a possible bond between anti-perspiring and breast cancer. The most diffused assumption retained the possible role of aluminium parabenes and salts. However, so far, no epidemiologic exploratory study showed the assumption that the use of the deodrants affected the increase in breast cancer at the woman.
No the scientific proof
An group of expert of the review Bulletin of Cancer, Official body of the French company of Cancera makes a scientific and detailed analysis in order to answer the anguish of the women on this subject. They thus reviewed 59 studies resulting from the library search and 19 various articles of methodology. Their conclusion? No scientific proof in favour of the assumption could be identified. Moreover, these experts explain that there does not remain any more any validated assumption likely to open on interesting ways of research. They affirm that this question does not constitute public health problems and that it appears useless to continue research on this subject.
Importance of the tracking of breast cancer
A minority of breast cancers is related to a family hereditary form which occurs, generally, at a young age, one of the independent factors of risk remaining the estrogenes. Thus the prevention of this female plague rests especially on tracking by mammograhie.
Breast cancer remains the most frequent cancer of the woman in the Western countries: it touches a woman on nine, primarily after the menopause. If breast cancer is detected early, the more the chances of cure. Thanks to early tracking, half of breast cancers are detected whereas they measure less than 2 cm. This level of detection makes it possible to reach very high rates of cure while reducing considerably the aggressiveness of the treatments applied. Any age, you must be regularly followed by an attending physician or a gynaecologist who will prescribe you the examinations necessary, in particular if it estimates that you have family factors of cancer risk of the centre. This medical monitoring must take place every 6 months or every year as from 30 years.